The nuclear factor erythroid 2-related factor 2/p53 axis in breast cancer

被引:20
|
作者
Xia, Lei [1 ]
Ma, Wenbiao [1 ]
Afrashteh, Ahmad [2 ]
Sajadi, Mir Amirhossein [3 ]
Fakheri, Hadi [3 ]
Valilo, Mohammad [4 ]
机构
[1] Qinghai Prov Peoples Hosp, Surg Oncol Ward 2, Xining, Qinghai, Peoples R China
[2] Tabriz Univ Med Sci, Dept Periodont, Fac Dent, Tabriz, Iran
[3] Tabriz Univ Med Sci, Paramed Fac, Tabriz, Iran
[4] Urmia Univ Med Sci, Dept Biochem, Fac Med, Orumiyeh, Iran
关键词
breast cancer; drug resistance; Kelch-like ECH-associated protein 1 (Keap1); nuclear factor erythroid 2-related factor 2 (Nrf2); p53; OXIDATIVE STRESS; TP53; MUTATIONS; P53; PROTEIN; MUTANT P53; CONFERS CHEMORESISTANCE; SIGNALING PATHWAY; GENE-EXPRESSION; CELL-SURVIVAL; RISK-FACTORS; DUAL ROLES;
D O I
10.11613/BM.2023.030504
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
One of the most important factors involved in the response to oxidative stress (OS) is the nuclear factor erythroid 2-related factor 2 (Nrf2), which regulates the expression of components such as antioxidative stress proteins and enzymes. Under normal conditions, Kelch- like ECH-associated protein 1 (Keap1) keeps Nrf2 in the cytoplasm, thus preventing its translocation to the nucleus and inhibiting its role. It has been established that Nrf2 has a dual function; on the one hand, it promotes angiogenesis and cancer cell metastasis while causing resistance to drugs and chemotherapy. On the other hand, Nrf2 increases expression and proliferation of glutathione to protect cells against OS. p53 is a tumour suppressor that activates the apoptosis pathway in aging and cancer cells in addition to stimulating the glutaminolysis and antioxidant pathways. Cancer cells use the antioxidant ability of p53 against OS. Therefore, in the present study, we discussed function of Nrf2 and p53 in breast cancer (BC) cells to elucidate their role in protection or destruction of cancer cells as well as their drug resistance or antioxidant properties.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism
    Smolkova, Katarina
    Miko, Edit
    Kovacs, Tunde
    Leguina-Ruzzi, Alberto
    Sipos, Adrienn
    Bai, Peter
    ANTIOXIDANTS & REDOX SIGNALING, 2020, 33 (13) : 966 - 997
  • [2] Nuclear Factor Erythroid 2-Related Factor 2 in Vitiligo
    Romano-Lozano, V.
    Cruz-Avelar, A.
    Pedrero, M. L. Peralta
    ACTAS DERMO-SIFILIOGRAFICAS, 2022, 113 (07): : 705 - 711
  • [3] Nuclear factor erythroid 2-related factor 2 and autophagy regulation in cancer development
    Waleska Dornas
    Biophysical Reviews, 2022, 14 : 1105 - 1107
  • [4] Nuclear factor erythroid 2-related factor 2 and autophagy regulation in cancer development
    Dornas, Waleska
    BIOPHYSICAL REVIEWS, 2022, 14 (05) : 1105 - 1107
  • [5] Nuclear factor-erythroid 2-related factor 2 as a chemopreventive target in colorectal cancer
    Saw, Constance Lay Lay
    Kong, Ah-Ng Tony
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (03) : 281 - 295
  • [6] Ganoderic acid targeting nuclear factor erythroid 2-related factor 2 in lung cancer
    Gill, Balraj Singh
    Kumar, Sanjeev
    Navgeet
    TUMOR BIOLOGY, 2017, 39 (03)
  • [7] Modulation of liver regeneration by the nuclear factor erythroid 2-related factor 2
    Bellanti, Francesco
    Serviddio, Gaetano
    Vendemiale, Gianluigi
    ADVANCES IN REDOX RESEARCH, 2023, 7
  • [8] Role of Nuclear Factor Erythroid 2-Related Factor 2 in Diabetic Nephropathy
    Cui, Wenpeng
    Min, Xu
    Xu, Xiaohong
    Du, Bing
    Luo, Ping
    JOURNAL OF DIABETES RESEARCH, 2017, 2017
  • [9] Nuclear factor erythroid 2-related factor 2 in human papillomavirus-related cancers
    Cruz-Gregorio, Alfredo
    Aranda-Rivera, Ana Karina
    Pedraza-Chaverri, Jose
    REVIEWS IN MEDICAL VIROLOGY, 2022, 32 (03)
  • [10] Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases
    Ito, Marie
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2020, 29 (01): : 128 - 135